1
|
Cuccuini W, Collonge-Rame MA, Auger N, Douet-Guilbert N, Coster L, Lafage-Pochitaloff M. Cytogenetics in the management of bone marrow failure syndromes: Guidelines from the Groupe Francophone de Cytogénétique Hématologique (GFCH). Curr Res Transl Med 2023; 71:103423. [PMID: 38016422 DOI: 10.1016/j.retram.2023.103423] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2023] [Revised: 10/03/2023] [Accepted: 10/17/2023] [Indexed: 11/30/2023]
Abstract
Bone marrow failure syndromes are rare disorders characterized by bone marrow hypocellularity and resultant peripheral cytopenias. The most frequent form is acquired, so-called aplastic anemia or idiopathic aplastic anemia, an auto-immune disorder frequently associated with paroxysmal nocturnal hemoglobinuria, whereas inherited bone marrow failure syndromes are related to pathogenic germline variants. Among newly identified germline variants, GATA2 deficiency and SAMD9/9L syndromes have a special significance. Other germline variants impacting biological processes, such as DNA repair, telomere biology, and ribosome biogenesis, may cause major syndromes including Fanconi anemia, dyskeratosis congenita, Diamond-Blackfan anemia, and Shwachman-Diamond syndrome. Bone marrow failure syndromes are at risk of secondary progression towards myeloid neoplasms in the form of myelodysplastic neoplasms or acute myeloid leukemia. Acquired clonal cytogenetic abnormalities may be present before or at the onset of progression; some have prognostic value and/or represent somatic rescue mechanisms in inherited syndromes. On the other hand, the differential diagnosis between aplastic anemia and hypoplastic myelodysplastic neoplasm remains challenging. Here we discuss the value of cytogenetic abnormalities in bone marrow failure syndromes and propose recommendations for cytogenetic diagnosis and follow-up.
Collapse
Affiliation(s)
- Wendy Cuccuini
- Laboratoire d'Hématologie, Unité de Cytogénétique, Hôpital Saint-Louis, Assistance Publique Hôpitaux de Paris (APHP), 75475, Paris Cedex 10, France.
| | - Marie-Agnes Collonge-Rame
- Oncobiologie Génétique Bioinformatique UF Cytogénétique et Génétique Moléculaire, CHU de Besançon, Hôpital Minjoz, 25030, Besançon, France
| | - Nathalie Auger
- Laboratoire de Cytogénétique/Génétique des Tumeurs, Gustave Roussy, 94805, Villejuif, France
| | - Nathalie Douet-Guilbert
- Laboratoire de Génétique Chromosomique, CHU Brest, Hôpital Morvan, 29609, Brest Cedex, France
| | - Lucie Coster
- Laboratoire d'Hématologie, Secteur de Cytogénétique, Institut Universitaire de Cancérologie de Toulouse, CHU de Toulouse, 31059, Toulouse Cedex 9, France
| | - Marina Lafage-Pochitaloff
- Laboratoire de Cytogénétique Hématologique, CHU Timone, Assistance Publique Hôpitaux de Marseille (APHM), Aix Marseille Université, 13005, Marseille, France
| |
Collapse
|
2
|
Coster L, Huguet F, Canali A, Rieu JB, De Mas VM. An ETV6::NTRK3 fusion transcript in a core-binding factor acute myeloid leukemia. EJHaem 2023; 4:867-868. [PMID: 37601839 PMCID: PMC10435688 DOI: 10.1002/jha2.706] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/05/2023] [Accepted: 04/27/2023] [Indexed: 08/22/2023]
Affiliation(s)
- Lucie Coster
- Haematology Laboratory Toulouse University Cancer Institute-Oncopole Toulouse France
| | - Françoise Huguet
- Haematology Department Toulouse University Cancer Institute-Oncopole Toulouse France
| | - Alban Canali
- Haematology Laboratory Toulouse University Cancer Institute-Oncopole Toulouse France
| | - Jean-Baptiste Rieu
- Haematology Laboratory Toulouse University Cancer Institute-Oncopole Toulouse France
| | - Véronique Mansat- De Mas
- Haematology Laboratory Toulouse University Cancer Institute-Oncopole Toulouse France
- Medical University Toulouse University III Jean-Paul Sabatier Toulouse France
| |
Collapse
|
3
|
Brett VE, Lechevalier N, Trimoreau F, Dussiau C, Dimicoli-Salazar S, Coster L, Luquet I, Nadal N, Ribourtout B, Chapiro E, Lefebvre C, Tondeur S, Balducci E, Nguyen-Khac F, Borie C, Radford-Weiss I, Barin C, Eclache V, Mansier O, Bidet A. The presence of a chromosomal abnormality in cytopenia without dysplasia identifies a category of high-risk clonal cytopenia of unknown significance. Genes Chromosomes Cancer 2023; 62:139-151. [PMID: 36412977 DOI: 10.1002/gcc.23107] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 11/16/2022] [Accepted: 11/18/2022] [Indexed: 11/23/2022] Open
Abstract
Myelodysplastic syndromes (MDS) are hematological malignancies classically defined by the presence of cytopenia(s) and dysmorphic myeloid cells. It is now known that MDS can be preceded by a pre-malignant condition called clonal cytopenia of unknown significance (CCUS), which associates a clonality marker with cytopenia in the absence of criteria of dysplasia. However, to date, it is not clear whether chromosomal abnormalities should be considered in the definition of CCUS or if they carry a prognostic impact in CCUS patients. In this study, we analyzed the clinico-biological features and outcomes of 34 patients who presented with one or more cytopenias, an absence of significant dysplasia, and a presence of a chromosomal abnormality (CA). We named this entity chromosomal abnormality with cytopenia of undetermined significance (CACtUS). We show that these patients are slightly older than MDS patients and that they more frequently presented with normocytic anemia. Most CACtUS patients exhibited only one unbalanced CA. The number and type of mutations were comparable between CACtUS patients and MDS patients. Regardless of the cytogenetic abnormality, the clinicobiological characteristics, overall survival, and risk of progression to high-risk (HR) MDS were similar between CACtUS patients and low-risk MDS patients. Thus, we suggest that CACtUS patients can be considered as HR-CCUS and should receive the follow-up regimen recommended for MDS patients.
Collapse
Affiliation(s)
| | | | - Franck Trimoreau
- Laboratoire d'Hématologie Biologique, CHU Limoges, Limoges, France
| | - Charles Dussiau
- Laboratoire d'Hématologie Biologique, CHU Bordeaux, Bordeaux, France.,INSERM U1034, Biology of cardiovascular disease, Pessac, France
| | | | - Lucie Coster
- Laboratoire d'Hématologie, CHU Toulouse, site IUCT-O, Toulouse, France.,Groupe Francophone de Cytogénétique Hématologique (GFCH)
| | - Isabelle Luquet
- Laboratoire d'Hématologie, CHU Toulouse, site IUCT-O, Toulouse, France.,Groupe Francophone de Cytogénétique Hématologique (GFCH)
| | - Nathalie Nadal
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Service de génétique chromosomique et moléculaire, CHU Dijon, Dijon, France
| | - Bénédicte Ribourtout
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Laboratoire d'Hématologie, CHU Angers, Angers, France
| | - Elise Chapiro
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.,Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138; Sorbonne Université, Paris, France
| | - Christine Lefebvre
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Laboratoire de Cytogénétique des Hémopathies, CHU Grenoble Alpes, Grenoble, France
| | - Sylvie Tondeur
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Laboratoire d'Hématologie, CHU St-Etienne, St Etienne, France
| | - Estelle Balducci
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Laboratoire d'Hématologie, Hôpital Paul Brousse, APHP, Paris, France
| | - Florence Nguyen-Khac
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Service d'Hématologie Biologique, Hôpital Pitié-Salpêtrière, AP-HP, Paris, France.,Cell Death and Drug Resistance in Lymphoproliferative Disorders Team, Centre de Recherche des Cordeliers, INSERM UMRS 1138; Sorbonne Université, Paris, France
| | - Claire Borie
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Laboratoire d'Hématologie, Hôpital Paul Brousse, APHP, Paris, France
| | - Isabelle Radford-Weiss
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Laboratoire de Cytogénétique, Hôpital Necker-Enfants Malades, APHP, Paris, France
| | - Carole Barin
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Laboratoire de cytogénétique hématologique, Service de génétique, CHU Bretonneau, Tours, France
| | - Virginie Eclache
- Groupe Francophone de Cytogénétique Hématologique (GFCH).,Hopital Pitié-Salpétrière, AP-HP, France
| | - Olivier Mansier
- Laboratoire d'Hématologie Biologique, CHU Bordeaux, Bordeaux, France.,INSERM U1034, Biology of cardiovascular disease, Pessac, France
| | - Audrey Bidet
- Laboratoire d'Hématologie Biologique, CHU Bordeaux, Bordeaux, France.,Groupe Francophone de Cytogénétique Hématologique (GFCH)
| | | |
Collapse
|
4
|
Lapierre L, Syrykh C, Largeaud L, Cabarrou B, Filleron T, Oberic L, Kanoun S, Coster L, Laurent C, Branco B, Gadaud N, Récher C, Brechemier D, Balardy L, Vergez F, Ysebaert L, Gauthier M. "Accelerated phase" chronic lymphocytic leukemia: still an intermediate risk disease in the era of targeted therapies. Hematol Oncol 2022; 40:805-808. [PMID: 35246868 DOI: 10.1002/hon.2985] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
N/A This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Léopoldine Lapierre
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France
| | - Charlotte Syrykh
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Anatomopathologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | - Laetitia Largeaud
- Université de Toulouse, UPS, Toulouse, France.,Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Laboratoire d'Oncohématologie, Toulouse, France
| | - Bastien Cabarrou
- Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département de biostatistiques, Toulouse, France
| | - Thomas Filleron
- Institut Claudius Regaud (ICR), Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département de biostatistiques, Toulouse, France
| | - Lucie Oberic
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France
| | - Salim Kanoun
- Institut Claudius Regaud (ICR) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Département de médecine nucléaire, Toulouse, France
| | - Lucie Coster
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Laboratoire d'Oncohématologie, Toulouse, France
| | - Camille Laurent
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Anatomopathologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | - Benoît Branco
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France
| | - Noémie Gadaud
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | - Christian Récher
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | - Delphine Brechemier
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Oncogériatrie, Toulouse, France
| | - Laurent Balardy
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Oncogériatrie, Toulouse, France
| | - François Vergez
- Université de Toulouse, UPS, Toulouse, France.,Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Laboratoire d'Oncohématologie, Toulouse, France
| | - Loïc Ysebaert
- Centre Hospitalo-universitaire (CHU) de Toulouse, Institut Universitaire du Cancer de Toulouse-Oncopole (IUCT-O), Service d'Hématologie, Toulouse, France.,Université de Toulouse, UPS, Toulouse, France
| | | |
Collapse
|
5
|
Coster L, Mansat‐De MAS V, Largeaud L, Voisin S, Corre J, Gauthier M. Chronic Myeloid Leukaemia with isolated massive thrombocytosis and BCR‐ABL1 detection failure using RT‐MLPA (positive RT‐qPCR). eJHaem 2021; 2:655-656. [PMID: 35844709 PMCID: PMC9175668 DOI: 10.1002/jha2.207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 03/08/2021] [Revised: 04/12/2021] [Accepted: 04/14/2021] [Indexed: 11/14/2022]
Affiliation(s)
- Lucie Coster
- Service d'Hématologie biologique Centre Hospitalier Universitaire de Toulouse IUCT‐O Toulouse France
| | - Véronique Mansat‐De MAS
- Service d'Hématologie biologique Centre Hospitalier Universitaire de Toulouse IUCT‐O Toulouse France
- Université Paul Sabatier Toulouse III Toulouse France
| | - Laetitia Largeaud
- Service d'Hématologie biologique Centre Hospitalier Universitaire de Toulouse IUCT‐O Toulouse France
- Université Paul Sabatier Toulouse III Toulouse France
| | - Sophie Voisin
- Service d'Hématologie biologique Centre Hospitalier Universitaire de Toulouse IUCT‐O Toulouse France
| | - Jill Corre
- Service d'Hématologie biologique Centre Hospitalier Universitaire de Toulouse IUCT‐O Toulouse France
- Université Paul Sabatier Toulouse III Toulouse France
| | - Martin Gauthier
- Service d'Hématologie clinique Centre Hospitalier Universitaire de Toulouse IUCT‐O Toulouse France
| |
Collapse
|
6
|
Rieu J, Coster L, Corre J, Tavitian S, Recher C, Huynh A, Picard M, Derreumaux C, Bertoli S, Vergez F, Largeaud L. A case of cup-like blasts associated with B-lymphoblastic leukemia without NPM1 and FLT3 internal tandem duplication mutations. EJHaem 2020; 1:589-592. [PMID: 35845019 PMCID: PMC9175993 DOI: 10.1002/jha2.91] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 08/12/2020] [Revised: 08/18/2020] [Accepted: 08/19/2020] [Indexed: 06/15/2023]
Affiliation(s)
- Jean‐Baptiste Rieu
- Haematology LaboratoryCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Lucie Coster
- Haematology LaboratoryCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Jill Corre
- Haematology LaboratoryCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Suzanne Tavitian
- Clinical Haematology UnitCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Christian Recher
- Clinical Haematology UnitCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Anne Huynh
- Clinical Haematology UnitCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Muriel Picard
- Intensive Care UnitCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Celine Derreumaux
- Intensive Care UnitCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Sarah Bertoli
- Clinical Haematology UnitCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Francois Vergez
- Haematology LaboratoryCancer University Institute of Toulouse – OncopoleToulouseFrance
| | - Laetitia Largeaud
- Haematology LaboratoryCancer University Institute of Toulouse – OncopoleToulouseFrance
| |
Collapse
|
7
|
Simard JF, Arkema EV, Sundstrom A, Geborek P, Saxne T, Baecklund E, Coster L, Dackhammar C, Jacobsson L, Feltelius N, Lindblad S, Rantapaa-Dahlqvist S, Klareskog L, van Vollenhoven RF, Neovius M, Askling J. Ten years with biologics: to whom do data on effectiveness and safety apply? Rheumatology (Oxford) 2010; 50:204-13. [DOI: 10.1093/rheumatology/keq326] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Coster L. A happy ending; a nursing care study. Nurs Times 1966; 62:777. [PMID: 5932123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/21/2023]
|
9
|
|
10
|
Coster L. Eine neue Methode, rostfreien Stahl zu löten. J Orofac Orthop 1933. [DOI: 10.1007/bf02001862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
|